By SPC News Staff
The FDA Oncologic Drugs Advisory Committee (ODAC) voted against a recommendation for selinexor (Karyopharm Therapeutics), which is seeking an indication for patients with relapsed-refractory multiple myeloma, because committee members could not decide whether the benefits outweighed the risks.
Selinexor is a first-in-class, oral selective inhibitor of nuclear export (or SINE) compound. Selinexor works by binding with and inhibiting the nuclear export protein XPO1 (also called